Frequently asked questions
Frequently asked questions
About our company
What is Follicum?
Follicum is a biotech company focusing on drugs based on peptides derived from human proteins. Our prime focus is to stimulate hair growth with promising results with our drug candidate FOL-005 in recently concluded clinical trials. The drug candidate, FOL-014, has demonstrated an ability to increase the release insulin in pre-clinical models. The company was founded in 2011 and listed on the Swedish small cap exchange AktieTorget in 2014.
Read more: About Follicum
The management of Follicum?
Jan Alenfall, CEO
Maria Ekblad, R & D Director
Gunnar Gårdemyr, CBO
Research group: Pontus Dunér, Anki Knutsson and Anna Hultgårdh-Nilsson
Read more: Management
The board of directors?
Chairman of the Board: Dr Fredrik Buch
Members of the board: Prof Emeritus Lars H Bruzelius, Dr Elisabeth Svanberg, Dr Anna Hultgårdh-Nilsson
Read more: Board of Directors
Is Follicum listed on a public exchange?
Follicum AB was listed on the Swedish small cap exchange AktieTorget in November 2014.
Read more: Share information
The research areas of Follicum?
Hair growth: Our most developed research project is focusing on the stimulation of hair growth for patients with unwanted hair loss (partial or whole baldness). Our drug candidate FOL-005 has been through a clinical phase I/IIa trial in Berlin with good results. During late 2017, early 2018 another phase II trial will be carried out with healthy, bald individuals.
Read more: FOL-005 and regulation of hair growth
Diabetes: Our initial research on human proteins has continued and during Spring 2017 we observed a substantial release of insulin from mice pancreas in pre-clinical trials with a peptides derived from another protein, FOL-014. The basic research is carried out with different research groups at the University of Lund, the location of our founders. Our diabetes project is mainly carried out at the Clinical Research Centre (CRC) at the University Hospital in Malmö – managed by professor Jan Nilssons research group. This is mainly due to a large governmental founding on diabetes from the Swedish Foundation of Strategic Research.
Read more: FOL-014 Pre-clinical research
How do we commercialise our products?
Our future revenues are planned to come from licensing or sale of parts or whole projects to pharmaceutical and/or financial stakeholders. At the moment we do not see Follicum as a production or marketing organisation in the future. The timing will be essential for each of our development projects and we may seek an exit for a drug candidate even before the clinical phases are finalised.
Our projects in hair growth
What is alopecia or hair loss?
Human hair – both to much or to little – is an important social factor in our society. Millions of people suffer from early hair loss (alopecia) and more millions, often women, suffer from unwanted hair growth (hirsutism). Many times, with psychic traumas because of the hair loss. There are no real efficient and secure treatment available, suitable for both men and women.
Read more: Hair growth
What is hirsutism (unwanted hair growth)?
There are two distinct markets for removal of unwanted hair. First the medical where the hirsutism condition gives women a strong male hair growth. The second is the cosmetic market (non-medical). Each culture in the world has developed social norms for the status of hair growth on the body. The cosmetic reasons for hair removal may range from pure aesthetic to religion based.
Read more: Hirsutism
The mechanisms of FOL-005?
Our latest research has identified receptors in human hair follicle cells that our lead candidate FOL-005 binds to. The newly acquired knowledge paves the way for a better understanding of how FOL-005 can be used for treatment of hair loss, and a significant milestone in the continued development of FOL-005.
Press release Receptors for FOL-005: Important new receptors for Follicum’s lead candidate FOL-005 in hair follicle cells identified
Our continued development of FOL-005?
Follicum recently contracted two leading institutions for our up-coming clinical trial. First the CRC at the Charité University in Berlin (which carried out our recent phase I/IIa trial) and Bioskin in Hamburg, a CRO specialised in dermatology. In our next trial, which will include 60 individuals, our peptide will be administered on the human scalp through injections.
Millions of people, more men than women, experience partial or total hair loss. 2017 the market for hair loss products is estimated to 7,6 MUSD and the forecast for 2024 is close to 12 MUSD (Report: Grand View Research: Alopecia Treatment Market 2017).
The main substance in many products on the market is minoxidil. Many individuals do not response well to this substance, with side effects as hair loss, headaches and skin irritation.
Thus, there is a large potential for an efficient and safe drug against hair loss for many patients.
Our projects in diabetes
What is diabetes?
Diabetes is a scourge which grows every year and with the main number of patients (90 %) which is caused by unhealthy diet, smoking, alcohol consumption and lack of physical activity; defined as diabetes type 2. A smaller part of the diabetes patients, diabetes type 1, is an inherited condition in younger people. The World Health Organisation, WHO, estimates the number of individuals with diabetes to 420 million world-wide. Within 20 years, the number of patients with diabetes 2 is expected to be doubled. Adding to this is a huge number of un-diagnosed individuals.
Read more: About diabetes
Our studies on diabetes and FOL-014?
Our pre-clinical research with Professor Anna Hultgårdh Nilsson, at the Centre of Bio Medicine in Lund, BMC, and Professor Jan Nilsson at the Clinical Research Centre at the University of Lund, CRC, have resulted in the new peptide FOL-014. This peptide has shown to bind in the pancreas, creating an increased release of insulin from the pancreas in mice. Further pre-clinical trials will be performed to investigate the positive effects of FOL-014.
Read more: FOL-014: Pre-clinical research
Diabetes market estimates?
The market for treatment of diabetes type 2 is divided in different sub-groups with annual sales of more than 60 BUSD. The major products are DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors as well as different versions of insulin treatment.
Read more: About diabetes
Our continued development?
Further pre-clinical trials in diabetes will be conducted to investigate further effects of FOL-014. See above ”Our studies on diabetes and FOL-014”.